Development asset linked to CNS Pharmaceuticals in public FDA and regional records. Mechanism: GABA-A receptor; anion channel positive modulator.
- Mechanism
- GABA-A receptor; anion channel positive modulator
pharma · Malaria · Pharmacokinetics · CNSP
CNS Pharmaceuticals
CNS Pharmaceuticals drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Houston, TX 77027, US HQ
2017 Founded
12 Employees
Public company Type
CNSP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Houston, TX 77027, US
- Founded
- 2017
- Employees
- 12
- Programs
- 21
- Drugs
- 18
- Patents
- 0
CNS Pharmaceuticals pipeline
Portfolio lens on 18 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CNS Pharmaceuticals drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records.
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records.
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records.
-
dabigatran etexilate
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in CNS Pharmaceuticals's portfolio. Mechanism: Thrombin inhibitor.
- Mechanism
- Thrombin inhibitor
-
US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor modulator
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records.
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to CNS Pharmaceuticals in public FDA and regional records.